Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies.
Mostaghimi A, Ko J, Tosti A, McMichael A, Ohyama M, Ito T, Dutronc Y, Ball S, Yu G, Murage M, Chen YF, Chiasserini C, Wollenberg A. Mostaghimi A, et al. Among authors: chiasserini c. J Am Acad Dermatol. 2024 Oct;91(4):729-732. doi: 10.1016/j.jaad.2024.05.077. Epub 2024 Jun 7. J Am Acad Dermatol. 2024. PMID: 38852742 Free article. No abstract available.
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Kwon O, et al. Among authors: chiasserini c. Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. Am J Clin Dermatol. 2023. PMID: 36855020 Free PMC article. Clinical Trial.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. Among authors: chiasserini c. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Outcomes of down-titration in patients with severe scalp alopecia areata initially treated with baricitinib 4-mg: Week 152 data from BRAVE-AA2.
King B, Ohyama M, Senna M, Shapiro J, Dutronc Y, Durand F, Liu C, Yu G, Kolodsick J, Chiasserini C, Somani N, Piraccini BM. King B, et al. Among authors: chiasserini c. J Am Acad Dermatol. 2025 Feb;92(2):299-306. doi: 10.1016/j.jaad.2024.09.072. Epub 2024 Oct 22. J Am Acad Dermatol. 2025. PMID: 39447758 Clinical Trial.
Androgen receptor expression induces FGF2, FGF-binding protein production, and FGF2 release in prostate carcinoma cells: role of FGF2 in growth, survival, and androgen receptor down-modulation.
Rosini P, Bonaccorsi L, Baldi E, Chiasserini C, Forti G, De Chiara G, Lucibello M, Mongiat M, Iozzo RV, Garaci E, Cozzolino F, Torcia MG. Rosini P, et al. Among authors: chiasserini c. Prostate. 2002 Dec 1;53(4):310-21. doi: 10.1002/pros.10164. Prostate. 2002. PMID: 12430142